Transdermal physostigmine-absence of effect on topographic brain mapping

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Primary degenerative dementia (PDD) is a significant neurological condition characterized by progressive cognitive decline.
• Investigating potential therapeutic agents for PDD, such as physostigmine, is crucial for managing symptoms.
• Understanding the neurophysiologic impact of pharmacological interventions is essential for evaluating treatment efficacy.

Purpose of the Study:

• To assess the neurophysiologic effects of transdermal physostigmine (TPh) in patients diagnosed with primary degenerative dementia (PDD).
• To evaluate changes in electroencephalogram (EEG) spectra following a 2-month treatment period with TPh.

Main Methods:

• An open-label trial was conducted involving nine patients diagnosed with primary degenerative dementia (PDD).
• Electroencephalogram (EEG) data were collected from participants at baseline before treatment initiation.
• EEG data were re-recorded after two months of continuous transdermal physostigmine (TPh) administration for comparative analysis.

Main Results:

• Analysis of EEG spectra revealed no statistically significant changes in brain activity after two months of TPh treatment.
• Transdermal physostigmine (TPh) did not demonstrate a measurable neurophysiologic effect on the EEG profiles of PDD patients in this trial.

Conclusions:

• Transdermal physostigmine (TPh) did not yield significant neurophysiologic changes as measured by EEG spectra in patients with primary degenerative dementia (PDD).
• Further research may be needed to explore alternative physostigmine delivery methods or other therapeutic targets for PDD.